Truist raised the firm’s price target on Centene (CNC) to $45 from $42 and keeps a Buy rating on the shares. The company’s Q3 results saw top and bottom-line beats, consolidated health benefits ratio, HBR, that was a bit better, coupled with sequential improvement in Medicaid HBR and upped FY25 guidance, the analyst tells investors in a research note. High-level 2026 commentary was encouraging, with expectations of Medicaid profitability consistent with FY25, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNC:
- Centene price target lowered to $42 from $43 at UBS
- Centene price target raised to $45 from $43 at Oppenheimer
- Centene’s Uncertain Future: Sell Rating Amid Medicaid and Exchange Challenges
- Centene Corporation Reports Q3 2025 Financial Results
- Centene’s Earnings Call: Positive Outlook Amid Challenges